title: Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.
abstract: Anti-angiogenic therapy is a newly developed treatment method for malignant tumors. Endostatin has an anti-angiogenetic effect. Endostatin has also been shown to block the growth and metastasis of various cancers through the vascular system. However, there have so far been few reports on the relationship between endostatin and lymph node metastasis. In this study, we investigated the relationship between endostatin and the inhibition of lymph node metastasis. We first made recombinant adenovirus which expressed endostatin gene (Ad-end), and then performed the following experiments. Our findings showed Ad-end to inhibit the proliferation and tube formation of endothelial cells in vitro. In addition, Ad-end inhibited the growth of a human oral squamous cell carcinoma cell line (SQUU-B) implanted subcutaneously in the right flank of nude mice and orthotopically in the tongue of nude mice, and Ad-end also inhibited lymph node metastasis in orthotopic implantation. The number of CD31-positive blood vessels and 5'-nase-positive lymphatic vessels around Ad-end-infected tumors in tongue lesions was significantly lower than that in the control group. The down-regulation of vascular endothelial growth factor C (VEGF-C) in Ad-end-infected SQUU-B cells was recognized by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis. These findings suggested that endostatin inhibited lymphangiogenesis and lymph node metastasis by suppressing the production of VEGF-C in tumor cells.
authors.affiliation: Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, 1-1 Maidashi 3-chome, Higashi-ku, Fukuoka 812-8582, Japan. fukuokadaigaku2002@yahoo.co.jp
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Fukumoto
authors.forename: Masayo
authors.initials: M
authors.lastname: Morifuji
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Katakura
authors.forename: Masamichi
authors.initials: M
authors.lastname: Ohishi
authors.forename: Seiji
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D020533:Angiogenesis Inhibitors; D000818:Animals; D000970:Antineoplastic Agents; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D015536:Down-Regulation; D043169:Endostatins / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D042583:Lymphangiogenesis; D008207:Lymphatic Metastasis; D042601:Lymphatic Vessels / Q000378:metabolism; D051379:Mice; D009368:Neoplasm Transplantation; D014062:Tongue Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D042582:Vascular Endothelial Growth Factor C